FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three months ended March 31, 2009. For the three months ended March 31, 2009, the Company reported a net loss of $8.0 million, or $(0.43) per diluted share. This compares to a net income of $31.3 million, or $1.62 per diluted share, for the same period in 2008, which included a gain of $39.3 million resulting from the January 2008 sale of the Company’s orofacial therapeutics business. The Company ended the quarter with $88.8 million of cash and cash equivalents and investments, including $48.1 million in auction rate securities with a loan balance of $39.1 million against the auction-rate securities.
